Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Arrowhead Research Corporation F4Q08 (Qtr End 09/30/08) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions. We do have a question from Bill Boutin with Indusino Capital Management. Bill Boutin - Indusino Capital Management Just a couple of quick questions. First one is on the balance sheet. Given that you raised money in Arrowhead itself and you...
- Earnings calls 2008-12-15
Additional Resources
- Arrowhead Subsidiary, Calando Pharmaceuticals, Plans First to Humans Clinical Trial with Targeted, Nano-Delivered RNAi Therapeutic for Cancer
- PASADENA, Calif. -- Arrowhead Research Corporation (NASDAQ:ARWR) announced today that Calando, its majority owned subsidiary, together with City of Hope COH and the UCLA's Jonsson Cancer Center UCLA are planning a broad-based Phase I clinical trial to begin later this year for Calando's lead drug candidate, CALAA-01. "We expect...
- Research articles 2007-05-11
- Arrowhead Streamlines Business Model of Nanobiotech Subs, Calando Pharmaceuticals and Insert Therapeutics
- PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today a fundamental streamlining of its majority-owned subsidiaries, Calando Pharmaceuticals and Insert Therapeutics. Arrowhead will assume active management of the companies and focus resources on bringing multiple products to the clinic as rapidly as possible. Arrowhead's expanded role is intended to make...
- Research articles 2008-02-28
- Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
- PASADENA, Calif. -- Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ: ARWR) announced the publication in the Proceedings of the National Academy of Sciences PNAS, the scientific journal of the NAS, of the first non-human primate study to use multiple, systemic dosing...
- Research articles 2007-03-20
- Calando Pharmaceuticals Selects Agilent Technologies for siRNA Production
- DUARTE, Calif. & PALO ALTO, Calif. -- Calando Pharmaceuticals Inc., a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), has selected Agilent Technologies (NYSE:A) to manufacture the active siRNA component in its lead RNAi product, CALAA01. Calando was formed in 2005 to create, develop and commercialize proprietary technologies for the therapeutic...
- Research articles 2006-07-26
- Arrowhead Research Corporation Q1 2009 Earnings Call Transcript
- Question-and-Answer SessionOperator (Operator's instruction) Your first question comes from the line of Bill Boutin - Indusino Capital Management. Bill Boutin - Indusino Capital Management Real quick, could you guys go over again your plan, just on the Company, until the end of the year? Dr. Christopher Anzalone Sure, we...
- Earnings calls 2009-02-09
- Arrowhead Research Launches New Subsidiary to Focus on Delivery and Therapeutic Use of RNA Interference
- PASADENA, Calif. -- Arrowhead Research Corporation (NASDAQ:ARWR)(NASDAQ:ARWRW), announced today that it has launched Calando Pharmaceuticals, Inc., a new majority-owned subsidiary. Calando is a nanobiotechnology company focused on developing and commercializing exclusively licensed proprietary technologies for the therapeutic use of RNA interference, or "RNAi." Calando intends to combine novel RNAi delivery...
- Research articles 2005-02-22
- Arrowhead Announces the Issuance of Patent Covering a New Approach to Targeted Therapeutics
- PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today the U.S. Patent Office has issued U.S. Patent 7,018,609, Compositions Containing Inclusion Complexes. The patent is co-owned by the California Institute of Technology and Arrowhead's majority-owned subsidiary, Insert Therapeutics. In addition to covering applications pursued by Insert, the technology is licensed...
- Research articles 2006-04-12
- Arrowhead Subsidiaries Selected to Present at Credit Suisse Nanotechnology Conference
- PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR) announced today that Dr. Mark Davis, founder and technical consultant to majority-owned subsidiaries Insert Therapeutics and Calando Pharmaceuticals, and John C. Miller, Vice President, Business Development, have been selected to present at an invitation only Credit Suisse Nanotech Conference on September 6 and...
- Research articles 2006-08-31
- Calando Pharmaceuticals, UCLA Medical Center, City of Hope Announce Plans to Conduct First Cancer Clinical Trial for RNAi Therapeutic
- First Human Trials Using Targeted, Formulated siRNA to use NA interference Against Cancer
- Research articles 2007-05-11
- Arrowhead Research Subsidiary Founding Scientist, Dr. Mark E. Davis, Elected to the National Academy of Sciences
- PASADENA, Calif. -- Arrowhead Research Corporation (Nasdaq:ARWR), announced that Dr. Mark E. Davis, professor of chemical engineering at the California Institute of Technology, and founding scientist of Arrowhead subsidiaries Insert Therapeutics and Calando Pharmaceuticals, was elected to the National Academy of Sciences. Already a member of the National Academy of...
- Research articles 2006-05-05
- Newly Published Results Demonstrate Potential of Arrowhead Subsidiary's Technology as a New Tool in Fight against Cancer
- PASADENA, Calif. -- A leading cancer research journal has published animal studies showing that technology being developed by a subsidiary of Arrowhead Research Corp. (Nasdaq:ARWR) is effective in treating metastatic cancer in mice. The results, published in the October issue of Cancer Research, demonstrate that Calando Pharmaceuticals' proprietary delivery...
- Research articles 2005-10-04
- Stocks to Watch - ARWR, HELE, USBE, LABL.
- M2 PRESSWIRE-11 May 2007-SmallCapReview: Stocks to Watch - ARWR, HELE, USBE, LABLC1994-2007 M2 COMMUNICATIONS LTD RDATE:11052007 To learn more about featuring your company on SmallCapReview, email editor@smallcapreview.com. Arrowhead Research (Nasdaq: ARWR) Closed at $6.11. Announced today that Calando,...
- Research articles 2007-05-11
- << Previous
- page 1 of 1
- Next >>
